Gestational and Pathological Regulation of Placental Drug Transporters: Implications for Maternal–Fetal Drug Exposure and Developmental Safety
Whilst the placenta provides a partially selective barrier to drug transfer between maternal and fetal circulations, many drugs can still be transferred to the fetus to some degree. Whether a drug reaches the fetus will depend on drug properties, passive diffusion and active transport processes via placental transporters. This review provides an overview of how placental transporters are regulated throughout gestation and by pathology. This will impact on drug exposure in the mother and fetus. There are a number of transporter superfamilies including ATP-binding cassette transporters (ABC). The ABC transporters that have been identified within the placenta include P-glycoprotein (P-gp/ABCB1), breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance associated proteins (MRPs). Transporters from the solute carrier family (SLC) have also been identified including organic anion transporters, organic anion transporting polypeptides and organic cation transporters. Some drugs may not reach the fetus due to P-gp and BCRP acting as barriers to transfer by transporting selected substrates back into the maternal circulation. On the other hand SLC transporters play a role in drug uptake and exchange. There may be changes in transporter expression throughout gestation. Infection, inflammation, metabolic disturbances and other complications can affect placental transporter regulation. Molecular factors have been shown to play a role including inflammation via cytokines, oxidative stress, hypoxia, hormone signalling and nuclear receptors. Genetic polymorphism and epigenetic mechanisms can also affect transporter expression. This may alter drug exposure to the fetus. However, it cannot be determined from placental transporter expression if a drug will transfer or if a drug will result in toxicity. Experimental models have been developed to investigate placental transporters including trophoblast models, ex-vivo placental perfusion, placental organoids, physiologically based pharmacokinetic modelling, and multi-omics. To improve prediction of fetal drug exposure, more functional data is required for specific gestations and diseases and also integrating clinical pharmacokinetics.
Authors
- Upadesh Lade
- Kunal Zode
- Priyanka Lilhare
- Revati Donode
- Yogini Kawale
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24415431
- Primary Topic
- Drug Transport and Resistance Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00